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Abstract
We previously mapped a type 2 diabetes (T2D) locus on chromosome 16 (Chr 16) in an F2 intercross from the BTBR T (+)t f
(BTBR) Lep
ob/ob and C57BL/6 (B6) Lep
ob/ob mouse strains. Introgression of BTBR Chr 16 into B6 mice resulted in a consomic
mouse with reduced fasting plasma insulin and elevated glucose levels. We derived a panel of sub-congenic mice and
narrowed the diabetes susceptibility locus to a 1.6 Mb region. Introgression of this 1.6 Mb fragment of the BTBR Chr 16 into
lean B6 mice (B6.16
BT36–38) replicated the phenotypes of the consomic mice. Pancreatic islets from the B6.16
BT36–38 mice
were defective in the second phase of the insulin secretion, suggesting that the 1.6 Mb region encodes a regulator of insulin
secretion. Within this region, syntaxin-binding protein 5-like (Stxbp5l) or tomosyn-2 was the only gene with an expression
difference and a non-synonymous coding single nucleotide polymorphism (SNP) between the B6 and BTBR alleles.
Overexpression of the b-tomosyn-2 isoform in the pancreatic b-cell line, INS1 (832/13), resulted in an inhibition of insulin
secretion in response to 3 mM 8-bromo cAMP at 7 mM glucose. In vitro binding experiments showed that tomosyn-2 binds
recombinant syntaxin-1A and syntaxin-4, key proteins that are involved in insulin secretion via formation of the SNARE
complex. The B6 form of tomosyn-2 is more susceptible to proteasomal degradation than the BTBR form, establishing a
functional role for the coding SNP in tomosyn-2. We conclude that tomosyn-2 is the major gene responsible for the T2D Chr
16 quantitative trait locus (QTL) we mapped in our mouse cross. Our findings suggest that tomosyn-2 is a key negative
regulator of insulin secretion.
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Introduction
Genetic factors are estimated to contribute approximately 50%
towards the risk of developing type 2 diabetes (T2D) [1]. Recent
genome-wide association studies have identified a number of
‘‘diabetes genes’’, gene loci that act in an additive manner and
conspire with obesity to augment the risk of T2D. Nearly all of
these genes affect b-cell function and/or the maintenance of b-cell
mass. Thus, it appears that diet and obesity place demands on b-
cells for insulin by causing insulin resistance, but the genetic
bottleneck that can lead to T2D involves genes that affect the
capacity of pancreatic b-cells to meet the increased insulin
demand.
Mouse intercrosses provide high power to detect linkage of gene
loci to physiological traits related to obesity and diabetes. The
mapping resolution of these intercrosses is typically not fine
enough to identify individual genes. However, by generating
panels of congenic strains carrying meiotic recombinations within
disease loci, it is possible to map the genes underlying those loci
with high resolution. We recently reported the positional cloning
of a T2D gene, Sorcs1, to sub-genetic resolution using this
approach [2]. Several other genes have been identified using a
similar approach; Zfp69, which encodes a transcription factor
involved in regulating glucose levels, was identified as the gene
underlying a diabetes susceptibility locus on mouse chromosome 4
[3]. Similarly, Lisch-like was identified as the gene underlying a
T2D locus on chromosome 1 and was shown to be involved in
regulating b-cell mass and plasma glucose levels [4].
Borrowing from microbial genetics, mouse genetic studies
employ a powerful tool for increasing the sensitivity to detect
heritable phenotypes. This involves sensitized screens wherein a
severe stressor provokes phenotypes that would otherwise be silent.
The stressor need not be a normal feature in human disease
pathogenesis to evoke phenotypes of great relevance to disease.
For example, the apoE-deficient mouse is the most widely used
animal model of atherosclerosis even though apoE deficiency is
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gene (Lep
ob) promotes morbid obesity in mice (Lep
ob/ob) and evokes
dysregulation of many pathways, enabling a greater understanding
of their regulatory mechanisms [6,7].
Using the Lep
ob mutation as a stressor, we found that the BTBR
T( +) (BTBR) mouse strain develops severe T2D, whereas the
C57BL/6 (B6) strain has moderate hyperglycemia and expands its
b-cell mass [8,9]. In an F2 intercross derived from these two
strains, we identified a T2D susceptibility locus on chromosome 16
(Chr 16) [9]. In the present study, we developed a panel of
congenic strains that enabled us to narrow this locus to just 0.94
Mb. Lean congenic mice that contain this genomic region derived
from the BTBR strain have elevated glucose and reduced insulin
levels. Islets from these mice show deficiencies in insulin secretion.
Within this small interval, we identified a novel diabetes
susceptibility gene, Syntaxin binding protein 5 like (Stxbp5l), also
known as Tomosyn-2. We showed that the tomosyn-2 protein is an
inhibitor of insulin secretion.
Results
Chr 16 consomic mice have increased fasting plasma
glucose and reduced insulin levels
We previously identified a fasting plasma glucose locus on Chr
16 from a Lep
ob/ob F2 intercross derived from the B6 and BTBR
mouse strains [9]. This locus acts in a fully dominant fashion on
plasma glucose and a semi-dominant fashion on fasting plasma
insulin [9]. The LOD peak on Chr 16 of the fasting glucose locus
from the F2 intercross is located at approximately 36–38 Mb
(Figure 1A). To determine if the Chr 16 locus could act
autonomously to affect T2D susceptibility, we derived a
chromosome substitution (i.e. consomic) mouse strain by
introgression of Chr 16 from BTBR into B6 ob/ob mice
(B6.16
BT Lep
ob/ob). The fasting plasma glucose levels of the
resulting consomic mice were significantly elevated at 4, 6, 8,
and 10 weeks compared to control (B6.16
B6 Lep
ob/ob) mice and
accounted for a major proportion of the plasma glucose phenotype
of the parental BTBR strain. Fasting plasma insulin levels were
reduced at 8 and 10-weeks in B6.16
BT Lep
ob/ob mice compared to
B6.16
B6 Lep
ob/ob mice (Figure 1B and 1C). These data suggested
that the hyperglycemia caused by BTBR Chr 16 substitution is
due to reduction in insulin levels. The data also indicate that the
locus on Chr 16 acts autonomously (i.e. in the absence of BTBR
alleles on other chromosomes) to affect glucose and insulin levels.
Congenic mice with a 1.6 Mb fragment of the BTBR Chr
16 have an insulin secretion defect
To assess whether the B6.16
BT Lep
ob/ob mice have a defect in
insulin secretion, we isolated pancreatic islets from 10-week old
B6.16
BT Lep
ob/ob mice and measured fractional insulin secretion in
response to high glucose (16.7 mM). We observed a ,50%
reduction in fractional insulin secretion in the B6.16
BT Lep
ob/ob
islets relative to control mice (B6.16
B6 Lep
ob/ob) (Figure 2, left
graph).
To avoid the metabolic complexities that are attributed to the
leptin mutation in the Lep
ob/ob mice [10], we performed
experiments in lean mice. Islets isolated from the congenic
Figure 1. Chromosome 16 of BTBR mice contains diabetogenic
alleles. A) Consomic mice were generated by introgression of either a
B6 or BTBR mouse chromosome 16 in the B6 Lep
ob/ob mice. The LOD
curve corresponds to a fasting glucose QTL from an F2 cross of (B6 x
BTBR) Lep
ob/ob mice. The approximate QTL position was derived using a
previously described method [9]. Fasting plasma glucose (B) and fasting
plasma insulin (C) were measured after a 4 h fast in male B6.16
B6 and
B6.16
BT Lep
ob/ob mice. Values are means 6 S.E. of N$34. * p#0.05 for
B6.16
BT Lep
ob/ob mice vs. control B6.16
B6 mice at each time point.
doi:10.1371/journal.pgen.1002323.g001
Figure 2. Effect of substitution of BTBR chromosome 16 in the
B6 Lep
ob/ob mice on insulin secretion. Islets were isolated from
Lep
ob/ob (left graph) and lean (right graph) 10-week B6.16
B6 and B6.16
BT
male mice. Lep
ob/ob islets were incubated with 16.7 mM glucose and the
islets from the lean mice were incubated with 3 mM 8-bromo cAMP at
11.1 mM sub-maximal glucose. Values are mean 6 S.E. of N$3. *p#0.05
for fractional insulin secretion from islets of B6.16
BT mice vs. control
B6.16
B6 mice.
doi:10.1371/journal.pgen.1002323.g002
Author Summary
Humans carry many genetic variants that confer small
effects on metabolic traits relevant to type 2 diabetes.
These effects are amplified by environmental stressors like
obesity. We used morbid obesity as a sensitizer to identify
genes that contribute to the diabetes susceptibility of the
BTBR mouse strain. Using mapping and breeding strate-
gies, we were able to narrow a genetic region to one
containing just 13 genes. One of these genes, tomosyn-2,
emerged as a prime candidate. Our functional studies
showed that tomosyn-2 is an inhibitor of insulin secretion,
and it binds to the proteins involved in the fusion of insulin
containing granules with the plasma membrane. We found
a coding mutation and demonstrated that this mutation
affects the stability of the protein product. Our work with
Tomosyn-2 provides new insights into the regulation of
insulin secretion and emphasizes that negative regulation
is critical for avoiding insulin-induced hypoglycemia.
Positional Cloning of a Type 2 Diabetes QTL
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BT and B6.16
B6 lean mice were treated with 8-bromo cAMP
(3 mM) at sub-maximal glucose (11.1 mM); this combination of
secretagogues was used for phenotyping lean congenic mice
because it evoked more insulin secretion from lean islets than
glucose alone. We observed ,40% reduction in fractional insulin
secretion in islets isolated from the lean B6.16
BT mice relative to
the lean control B6.16
B6 mice (Figure 2, right graph). The data
show that the insulin secretion defect, although initially mapped in
a screen of F2 mice sensitized by the Lep
ob mutation, manifests itself
independent of leptin deficiency.
To investigate the region of the BTBR Chr 16 that confers the
insulin secretion defect, a panel of lean congenic mouse strains was
generated from the B6.16
BT mice, each containing a small
introgressed region from the BTBR Chr 16 in the B6 background
(Figure 3, left panel). The B6/BTBR boundaries for each congenic
strain were determined via microsatellite marker, single nucleotide
polymorphism (SNP) sequencing or deletion/insertion polymor-
phism (DIP) sequencing (Dataset S1). By phenotyping each strain,
we were able to fine-map the location of the gene responsible for
the insulin secretion defect.
Islets were isolated from each lean congenic mouse strain and
fractional insulin secretion was determined in the presence of
3 mM 8-bromo cAMP at sub-maximal 11 mM glucose. The islets
isolated from the lean congenic mice that carry the 2 Mb Chr 16
derived from the BTBR strain (B6.16
BT36–38) were defective in
insulin secretion when compared to islets isolated from congenic
mice B6.16
B6, B6.16
BT37–55, or B6.16
BT24–37 (Figure 3, right
panel). The overlapping region of BTBR Chr 16 represented by
congenic strains, B6.16
BT36–38 and B6.16
BT37–55 enabled us to
further narrow the region to 1.6 Mb. Islets isolated from congenic
mice, B6.16
BT24–55, B6.16
BT24–47, or B6.16
BT24–38, which con-
tained the 1.6 Mb region derived from the BTBR strain, also
displayed a reduced level of insulin secretion, indicating that this
1.6 Mb region contains a gene responsible for regulating insulin
secretion.
The 1.6 Mb region of the BTBR Chr 16 is sufficient to
increase plasma glucose levels
We next determined the effect of introgression of the BT36–38
region of Chr 16 into B6 mice on susceptibility to obesity-induced
diabetes. Plasma insulin and glucose levels were determined in
random-fed 10-week B6.16
BT36–38 and control B6.16
B6 Lep
ob/ob
congenic mice. We observed a ,40% reduction in plasma insulin
levels in the B6.16
BT36–38 Lep
ob/ob compared to B6.16
B6 Lep
ob/ob
mice (Figure 4A). The reduction in plasma insulin was
accompanied by an increase in plasma glucose by ,100 mg/dL
(Figure 4C).
Although not nearly as dramatic as in the Lep
ob/ob mice, lean
congenic mice with the 36–38 Mb BTBR insert had a significant
reduction in plasma insulin and increase in plasma glucose
(Figure 4B and 4D, respectively). Detection of this very small rise
in plasma glucose required a very large sample size (n=80) to
achieve statistical significance. Clearly, we would not have found
this modest phenotype in a screen of lean mice, showing that
severe stressors like the Lep
ob mutation are required to identify
subtle allelic variation in QTLs that contribute to T2D risk.
Reduced insulin secretion in islets from lean B6.16
BT36–38
mice
Insulin secretion from pancreatic b-cells is biphasic. The first
phase represents a brief but rapid secretion from pre-docked
insulin granules in response to an initial depolarization of the
plasma membrane. Non-nutrient secretagogues like KCl predom-
inantly invoke the first phase of insulin secretion. The second
phase of insulin secretion is associated with metabolic signals
derived from the metabolism of fuel-based insulin secretagogues
like glucose. Glucose affects both the first and second phase of
insulin secretion. Briefly, glucose oxidation increases the ATP/
ADP ratio, resulting in the closure of ATP-sensitive KATP
channels. This causes depolarization of the plasma membrane
and influx of Ca
2+ via L-type voltage-dependent calcium channels.
Glucose promotes the second phase of insulin secretion without
causing a further increase in intracellular Ca
2+ levels. Diazoxide
Figure 3. Effect on insulin secretion of introgressing 1.6 Mb of
BTBR Chr 16 into B6 mice. Left panel: Congenic mice were
generated by introgression of varying fragments of the BTBR
chromosome 16 into the B6 mice. The B6/BTBR boundaries for each
congenic strain were determined via microsatellite marker, SNP
sequencing or DIP sequencing and are listed in Datasets S1 and S3.
Overlaying the congenic diagram is the position of the fasting glucose
QTL derived from a (B6 x BTBR) Lep
ob/ob F2 intercross. Right panel:
Fractional insulin secretion (% of islet insulin content) from the islets of
the 10-week lean congenic mice. Isolated islets were incubated for
45 min in KRB-based buffer containing low glucose (1.7 mM). After
45 min, the islets were exposed to 8-bromo cAMP (3 mM) at sub-
maximal glucose (11.1 mM) for another 45 min. Values are mean 6 S.E.
of N$3. *p#0.05 for fractional insulin secretion from islets of congenic
mice that contains the 1.6 Mb fragment of the BTBR chromosome 16
mice vs. congenic mice carrying this 1.6 Mb fragment derived from the
B6 strain.
doi:10.1371/journal.pgen.1002323.g003
Figure 4. Plasma insulin and glucose levels in the B6.16
BT36–38
male mice. Random-fed plasma insulin (A and B) and glucose (C and
D) were measured in 10-week Lep
ob/ob and lean B6.16
B6 and B6.16
BT36–38
male mice. Values are means 6 S.E. of N$10. *p#0.05 for plasma
glucose and insulin levels in B6.16
BT36–38 mice vs. control B6.16
B6 mice.
doi:10.1371/journal.pgen.1002323.g004
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+ channels, therefore adding this drug
along with 16.7 mM glucose will result only in the glucose-induced
second phase of insulin secretion and eliminates any glucose
induction of the first phase of insulin secretion [11–13].
To determine which phase of insulin secretion is defective in our
lean congenic B6.16
BT36–38 mice, we carried out perifusion studies
of isolated islets. Islets were perifused in Krebs-Henseleit Ringer
bicarbonate (KRB) buffer at the rate of 1 ml/min. The perfusate
was sampled every 30 sec, and the secreted insulin was measured
by ELISA. After an initial 60 min equilibration period in KRB
containing 1.7 mM glucose, islets were perifused for 10 min in
KRB containing 40 mM KCl and 250 mM diazoxide to elicit first
phase of insulin secretion. After 10 min, the islets were perifused
for an additional 30 min in KRB containing 16.7 mM glucose
with 40 mM KCl and 250 mM diazoxide to evoke the second
phase of insulin secretion. The peak of the first phase of insulin
secretion from B6.16
B6 islets was observed within 1–2 min of KCl
treatment. Following the first peak, the more sustained second
phase of insulin secretion was observed for an additional 30 min,
mimicking the well-studied biphasic kinetics of insulin secretion
[14].
Islets from B6.16
BT36–38 lean mice secreted ,40% less insulin
during the second phase than islets from the B6.16
B6 mice, as
determined by calculating the area under the curve (AUC)
(Figure 5A, 5B). There was also a small, but statistically significant
reduction of first-phase insulin secretion (p=0.044) (Figure 5A, 5B).
To complement the perifusion experiments, static insulin
secretion experiments were performed in islets isolated from the
B6.16
BT36–38 and control B6.16
B6 lean mice. Isolated islets were
incubated for 45 min in KRB containing 1.7 mM glucose.
Following a 45-min incubation, the islets were treated with
40 mM KCl in KRB containing 1.7 mM glucose. No difference in
fractional insulin secretion was observed in response to KCl
(Figure 6C, left panel). However, we observed a significant
decrease in fractional insulin secretion between islets from the
B6.16
BT36–38 lean mice and those from the control B6.16
B6 lean
mice in response to 15 mM arginine, 3 mM 8-bromo cAMP in
KRB containing 11 mM glucose, and 16.7 mM glucose alone
(Figure 5C, middle and right panels).
Sequencing and alignment of overlapping congenic
mouse strains narrowed the Chr 16 locus to 0.94 Mb
To further narrow the 1.6 Mb region of BTBR Chr 16
responsible for the phenotype, we used Agilent’s SureSelect Target
Enrichment to capture DNA from 35.35 Mb to 38.65 Mb on
mouse Chr 16. 55,336 RNA baits were designed using the Agilent
eArray and were used to enrich for our region from tail DNA of
the B6, BTBR, B6.16
BT36–38, B6.16
BT24–37and B6.16
BT24–38 mice.
DNA was sequenced by Next Generation Sequencing using an
Illumina GA IIx sequencer at the UW-Madison Biotechnology
Center. Using CLC Genomics 4.0.3 Software, we were able to
identify 470 SNPs; 3 non-synonymous coding SNPs and 46 DIPs
between the B6 and BTBR DNA (Figure 6A). 83 SNPs and 8 DIPs
were further confirmed by manual base reading to confirm the
accuracy of the software (listed in Dataset S2). Using this sequence
and known overlapping regions derived from the BTBR strain in
the sub-congenic strains exhibiting normal insulin secretion
(B6.16
BT24–37, B6.16
BT37–55), we were able to narrow the region
responsible for the insulin secretion defect to 0.94 Mb containing
13 genes (Figure 6B).
To identify the gene(s) responsible for the insulin secretion
defect, each candidate gene in the 0.94 Mb region was scored for
the difference in mRNA abundance between the islets B6.16
B6
and B6.16
BT36–38 islets, the presence of non-synonymous coding
SNPs, and similarity to a protein that have a functional role in
exocytosis. Tomosyn-2 or Stxbp5l (syntaxin binding protein 5-like)
quickly emerged as the top candidate gene. The mRNA
abundance of tomosyn-2 was elevated 2.6 fold in the B6.16
BT36–38
lean mice compared to control B6.16
B6 mice (Figure 7A). Tomosyn-
2 has a coding SNP (Ser-912RLeu). Eight other SNPs were also
identified in the introns and additional SNPs were identified in the
intergenic regions 59 and 39 of the gene (Dataset S1, Table S1).
The tomosyn-2 protein shares 95% identity in the C-terminal
Figure 5. Impaired insulin secretion in islets isolated from the
B6.16
BT36–38 mice. Islets were isolated from 10-week male control
B6.16
B6 mice (open circles) or B6.16
BT36–38 mice (filled circles). A) Islets
were preincubated for 60 min in low glucose (1.7 mM) and basal insulin
release was determined to establish a base line. After 60 min, the buffer
was changed to high potassium (40 mM) for another 10 min to obtain
first-phase insulin secretion. The glucose concentration was then
increased to 16.7 mM for 30 min to obtain second phase insulin.
Diazoxide (250 mM) was present in high potassium (40 mM) and high
glucose (16.7 mM) buffer. Eluted fractions containing secreted insulin
were collected and insulin concentration was determined by ELISA. B)
The area under the curve (AUC) was determined for the first (60.5–
70.5 min, left graph) and second phase (70.5–99.5 min, right graph) of
insulin secretion for the B6.16
BT36–38 and B6.16
B6 mice. Values are
means 6 S.E. of N=5. *p#0.05 for the first or second phase insulin
secretion from islets isolated from the B6.16
BT36–38 mice vs. control
B6.16
B6 mice. C) Static insulin secretion studies. Isolated islets were pre-
incubated for 45 min in low glucose (1.7 mM) buffer. After 45 min, the
islets were incubated in the presence of various insulin secretagogues.
Values are means 6 S.E. of N$4. *p#0.05 for static insulin secretion
from islets isolated from the B6.16
BT36–38 mice vs. control B6.16
B6 mice.
KCl=potassium chloride.
doi:10.1371/journal.pgen.1002323.g005
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tein receptor (SNARE) domain with several syntaxin-binding
proteins. Finally, a related protein, tomosyn-1, has been shown to
inhibit insulin secretion [15].
Increased expression of tomosyn-2 in islets of the
B6.16
BT36–38 lean mice
To understand the role of tomosyn-2 in the regulation of insulin
secretion, the expression of tomosyn-2 was determined in key
metabolic tissues; islet, liver, brain, cerebellum, kidney, adrenal,
adipose (perigonadal), heart, skeletal muscle (gastrocnemius,
soleus, and quadriceps) of the lean B6.16
BT36–38 and B6.16
B6
mice. The mRNA expression of tomosyn-2 in islets of the lean
B6.16
BT36–38 mice was ,2.6-fold higher than in islets from the
B6.16
B6 mice (Figure 7A). No allele-dependent difference in the
tomosyn-2 expression was observed in liver, brain, cerebellum,
kidney, adrenal, gastrocnemius, adipose, heart, soleus, and
quadriceps between the lean B6.16
BT36–38 and B6.16
B6 mice.
Four tomosyn-2 isoforms have been identified in mice: xb-, b, s,
and m-tomosyn-2. We determined the relative expression of the
tomosyn-2 isoforms in islets of the lean B6.16
BT36–38 and B6.16
B6
mice. We found that the b-tomosyn-2 isoform is the most abundant
isoform in mouse islets. This was confirmed by RT-PCR with a
primer pair that simultaneously amplified all of the tomosyn-2
isoforms (data not shown). The relative expression of b-tomosyn-2
and s-tomosyn-2 mRNA was ,6-fold higher in islets of the lean
B6.16
BT36–38 mice than in lean B6.16
B6 mice (Figure 7B). We
observed no significant difference between the two-congenic
mouse strains in the expression of xb- and m-tomosyn-2 isoforms.
Together, the data indicate that increased expression of tomosyn-2
may be responsible for the insulin secretion defect observed in the
lean B6.16
BT36–38 mice.
Figure 6. Insulin secretion defective region narrowed to 0.94 Mb on mouse chromosome 16 containing 13 genes. (A) Results from
Agilent SureSelect Target Enrichment of a 35.35 to 38.65 Mb region on mouse chromosome 16 followed by Next Generation Sequencing. Listed are
single nucleotide polymorphisms (SNP) and deletion insertion polymorphisms (DIP) between B6 and BTBR (listed in Dataset S2). Top: congenic maps
(with respective B6, BTBR, and unknown domains – boundaries were determined via SNP/DIP sequencing analysis listed in Dataset S1) of the strains
used to further define the region linked to the insulin secretion defect. Strains are listed as defective (*) or normal for insulin secretion (=). Those
SNPs and DIPs subjected to additional confirmation are represented as longer lines. Non-synonymous coding SNPs are highlighted with asterisks. The
boundaries of the inferred QTL region were defined by 1) the phenotypes of the sub-congenic strains and 2) sequencing of the region. We were able
to exclude the grey region common to B6.16
BT36–38 and B6.16
BT24–37 because 1) the latter strain is phenotypically like B6 and the former strain is
phenotypically like BTBR and 2) sequencing showed that the region is identical by descent between B6 and BTBR. Bottom: genes located in this
region as well as the breadth of the sequence coverage area (with gaps shown as tick marks along the line) (Gaps are listed in Dataset S4). The 0.94
Mb region containing the locus for defective insulin secretion is represented as an open box with arrowheads. B) Genes in the 0.94 Mb region with
their measured islet gene expression, fold change, and presence of non-synonymous coding SNPs. Not determined (nd), not significant (ns), * SNP
published in Mouse Phenome Database and UCSC Genome Browser, # SNP published only in UCSC Genome Browser.
doi:10.1371/journal.pgen.1002323.g006
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To investigate the role of tomosyn-2 in insulin secretion, we
investigated the effect of overexpressing b-tomosyn-2 in the
pancreatic b-cell line, INS1 (832/13). The cells were transfected
with GFP or b-tomosyn-2 expression plasmids. After 36 h, the cells
were incubated in KRB containing 1.5 mM glucose for 2 h.
Following the low glucose incubation, the cells were incubated for
additional 10 min or 2 h in 3 mM 8-bromo cAMP at 7 mM
glucose. Overexpressing b-tomosyn-2 decreased insulin secretion
by ,40% vs. GFP expressing cells at both 10 min and 2 h
(Figure 8A). No inhibition in fractional insulin secretion was
observed at low glucose (1.5 mM) (data not shown).
To determine if b-tomosyn-2 binds to syntaxin-1A and
syntaxin-4, key t-SNARE proteins involved in the fusion of insulin
granules to the plasma membrane, in vitro binding experiments
were performed using GST fused syntaxin-1A and syntaxin-4
recombinant proteins (soluble, lacking transmembrane domains)
by pull-down assays using glutathione beads. All isoforms of
tomosyn-2 bound to GST-syntaxin-1A and GST-syntaxin-4
(Figure 8B). The quantitation for the amount of bound tomosyn-
2 isoforms as a fraction of total is shown in Figure 8C. Tomosyn-1
was used as a positive control for binding. The GST tag did not
pull down tomosyn-1 or tomosyn-2, confirming that the
interaction between tomosyn-2 and syntaixn-1A and -4 is specific.
Together, these data suggests that the mechanism by which b-
tomosyn-2 inhibits insulin secretion involves binding to the
syntaxin proteins. This suggests the possibility that tomosyn-2,
like tomosyn-1, inhibits insulin secretion by preventing the binding
of VAMP2 to syntaxin-1A and syntaxin-4.
The B6 allelic product of B-tomosyn-2 is susceptible to
proteasomal degradation
We have shown that tomosyn-2 is a negative regulator of insulin
secretion and also binds to syntaxin-1A and syntaxin-4. To
investigate the possibility that the serine-912leucine SNP in
tomosyn-2 affects its stability, HEK293T cells were transfected
with empty vector (mock), b-tomosyn-2 (Serine-912), or b-
tomosyn-2 (Leucine-912). After 16 h, the cells were treated with
or without the proteasomal inhibitor, MG132 (100 mM) for 6 h.
The MG132 treatment rescued the B6 allelic form of the protein,
b-tomosyn-2 (serine-912), from proteasomal degradation by
,50% (Figure 9A and 9B). However, the BTBR allelic form of
the protein, b-tomosyn-2 (leucine-912) was not resistant to MG132
treatment, suggesting that an increased stability of the tomosyn-2
protein might be responsible for the attenuation in insulin
secretion from islets of the BTBR mice.
Discussion
Our pursuit of genes conferring susceptibility to obesity-induced
T2D focuses on two mouse strains that differ in diabetes
susceptibility. BTBR mice, when made obese with the Leptin
ob
mutation, are susceptible to T2D, whereas B6 mice with the same
mutation are relatively diabetes resistant [16,17]. The diabetes
susceptibility of the obese BTBR mice has multiple causes,
including an insulin secretion defect and a failure to increase b-cell
mass. As early as 4 weeks of age, islets from the obese B6, but not
BTBR mice have an increase in expression of a module of cell
cycle genes whereas the obese BTBR mice fail to induce the
expression of this module [16].
Through genetic mapping in an F2 intercross, we identified a
strong QTL on Chr 16 wherein the BTBR allele is linked to
increased glucose levels. In complex trait genetics, it is often the
case that gene loci do not act autonomously, but must act along
with specific alleles at other loci to exert their phenotypic effects
[18–20]. To determine if the Chr 16 locus acts autonomously, we
derived a chromosome substitution strain. Substitution of Chr 16
in the B6 strain with Chr 16 from the BTBR strain led to a
,100 mg/dl increase in glucose and a ,50% decrease in plasma
insulin. This established that a locus on Chr 16 acts autonomously
and is sufficient to account for a major part of the diabetes
phenotype of the BTBR mouse strain.
QTL mapping in an F2 intercross does not provide the
resolution required to identify individual genes. To narrow the
interval, we derived a panel of interval-specific congenic strains.
The strains were phenotyped on the basis of insulin secretion from
isolated islets, a far more robust phenotype than fasting glucose or
insulin levels. This enabled us to narrow the position of the QTL
to ,1 Mb, containing just thirteen genes. Of these thirteen genes,
tomosyn-2 was the only gene that had both altered mRNA
abundance and a coding SNP (S912L).
Recent studies by Williams et al. show that tomosyn-2 inhibits
exocytosis in PC12 cells [21]. Our experiments establish a role for
tomosyn-2 in insulin secretion. When we overexpressed tomosyn-2
in the pancreatic b-cell line INS1 (832/13), insulin secretion in
response to 8-bromo cAMP at sub-maximal glucose was
attenuated. In vitro GST-pull-down experiments showed that
tomosyn-2 has the ability to bind t-SNARE proteins, syntaxin-1A
and syntaxin-4. Syntaxin-1A is involved in the first phase and
syntaxin-4 is involved in regulating both the first and second phase
of insulin secretion [22]. These results establish that tomosyn-2,
Figure 7. Increased expression of tomosyn-2 gene in islets of
the B6.16
BT36–38 mice. Total mRNA was extracted from islets, liver,
brain, cerebellum, kidney, gastrocnemius, adipose, heart, soleus, and
quadriceps of the B6.16
BT36–38 and B6.16
B6 mice. Relative abundance
was determined by real-time PCR of the cDNA. The DCt was calculated
by subtracting the raw Ct of tomosyn-2 gene from the raw Ct of the b-
actin gene. A) The mRNA abundance of the tomosyn-2 gene in different
tissues. Left: tissues that have a relatively higher level of tomosyn-2
expression. Right: tissues with a relatively low level of tomosyn-2
expression. B) Relative expression of the tomosyn-2 isoforms in the
islets. Values are means 6 S.E. of N$4. *(p#0.05 for the expression of
tomosyn-2 gene in tissues of the B6.16
BT36–38 mice vs. control B6.16
B6
mice.
doi:10.1371/journal.pgen.1002323.g007
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fact that allelic variation in tomosyn-2 is sufficient to produce this
phenotype suggests that tomosyn-1 cannot compensate for this
deficiency, implying that their functions may not completely
overlap.
The mRNA abundance of tomosyn-2 was increased in the
congenic mouse strains expressing the BTBR allele. It is difficult to
determine if this difference in expression level is sufficient to
produce the difference in insulin secretion in islets of the two
mouse strains because it would require accurately titrating the
gene dosage (and the amount of protein product) in a null
background.
Sequence analysis revealed a SNP in tomosyn-2 (S912L). We
utilized a recent study showing that the proteasome inhibitor
MG132 increases the abundance of tomosyn-2 [21]. We found
that the S912L SNP abolishes the ability of MG132 to rescue
tomosyn-2 from proteasomal degradation, thus establishing a
functional role for the S912L SNP. Therefore, the decreased
insulin secretion associated with the BTBR allele might be the
result of increased stability of the tomosyn-2 protein as a
consequence of the SNP at amino acid 912. We also indentified
SNPs in the introns and the intergenic regions 59 and 39 of the
tomosyn-2 gene (Figure 7). The intronic SNPs may regulate the
stability of the tomosyn-2 mRNA and the intergenic SNPs might
affect the level of transcription of the gene.
To investigate the role of the S912L SNP in pancreatic islets, we
conducted perifusion experiments. Our perifusion experiments
demonstrated that islets from the B6.16
BT36–38 congenic mice were
defective in the 2
nd phase of insulin secretion. Our results suggest
that tomosyn-2 is likely to be responsive to metabolic signals. With
static incubation experiments, we tested various insulin secreta-
gogues. Islets with the BTBR allele of tomosyn-2 were clearly less
responsive to cAMP or arginine at sub-maximal glucose. These
secretagogues are involved in both phases of insulin secretion, but
the exact mechanisms by which they stimulate the 2
nd phase of
insulin secretion are not fully understood. The involvement of
tomosyn-2 provides a plausible new target for the actions of these
secretagogues.
We show that tomosyn-2, similar to tomosyn-1, binds to
syntaxin-1A and syntaxin-4 [24–27]. Recent studies suggest that
the binding to syntaxin is necessary but not sufficient for tomosyn-
29s inhibition of insulin secretion [21].
Our studies suggest that tomosyn-2 imposes a critical brake on
insulin secretion. This is particularly important during fasting
when inappropriate insulin secretion could cause life-threatening
hypoglycemia. We hypothesize that under fasting conditions when
Figure 8. Overexpression of tomosyn-2 inhibits insulin secretion in INS1 (832/13) cells and binds syntaxin-1A and -4. A) INS1 (832/13)
cells were plated in a 96-well plate (10
5 cells/well). After overnight incubation, the cells were cultured in RPMI supplemental media and transfected
with a bicistronic mammalian expression plasmid containing either GFP or b-tomosyn-2 and GFP. After 36 h of incubation, the insulin secretion was
measured. Fractional insulin secretion in response to 3 mM 8-bromo cAMP at 7 mM glucose from b-tomosyn-2 transfected cells was normalized to
that of cells transfected with GFP. Values are means 6 S.E. of N$4. * p#0.05 for the fractional insulin secretion from the cells overexpressing
tomosyn-2 vs. GFP expressing cells. B) HEK 293T cells were transfected with mock, tomosyn-1-myc, or tomosyn-2-myc isoforms (b, s, m, and xb)
mammalian expression plasmids. After 24 h, the cells were harvested and whole cell lysates (WCL) were prepared. GST-pull-down experiments were
performed as described in Methods. Ponceau S staining shows input of the GST fusion proteins. The overexpression of the exogenous protein in HEK
293T cells was determined by subjecting the WCL to western blot using anti-myc antibody. C) The graphs show the binding of each tomosyn-2
isoform relative to the amount of bound tomosyn-1. Values are means 6 S.E. of N=4.
doi:10.1371/journal.pgen.1002323.g008
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hypoglycemia.
In mice, the two tomosyn genes, tomosyn-1 and tomosyn-2,
encode seven alternatively spliced variants [23]. Tomosyn-1
contains three distinct isoforms (s, m, and b), whereas tomosyn-2
has four different spliced variants (s, m, b, and xb). The spliced
exons encode the hypervariable region (HVR), which in tomosyn-
1 has been shown to be subject to SUMOylation and PKA-
mediated phosphorylation [21,28]. The amino acid sequences of
tomosyn-1 and tomosyn-2 are quite similar in the N-terminal
WD40 repeats and C-terminal VAMP-like domain (VLD) [23].
Tomosyn-1 was identified in neurons as a syntaxin-1-binding
protein that sequesters t-SNAREs on the plasma membrane by
forming a ‘‘dead end’’, nonfusogenic SNARE complex, resulting
in inhibition of the formation of the SNARE complex [24,26].
Deletion of the tomosyn-1 gene in C.elegans or in mice resulted in
enhanced asynchronous neurotransmitter release [29,30]. Gain of
function studies demonstrated that tomosyn-1 is responsible for
inhibiting exocytosis of dense core granules in primary adrenal
chromaffin cells [27], PC12 cells [25], and pancreatic b-cells [15].
Moreover, in vitro biochemical evidence further supports the
conclusion that tomosyn-1 inhibits the formation of the SNARE
complex [31,32].
The Ca
2-independent inhibitory effects of the tomosyn-1 have
been attributed to the VLD. More recently, Yamamoto et al
demonstrated that in the presence of Ca
2+, tomosyn-1, via the N-
terminal WD40 domain, binds to synaptotagmin and inhibits
SNARE complex-mediated neurotransmitter release [26,30,33,34].
Together, the evidence is accumulating for tomosyn-1 as a negative
regulator of exocytosis in both the stimulated and unstimulated
states.
Insulin resistant animals compensate for their insulin resistance
and maintain normal glucose levels by increasing insulin secretion.
Our studies show that mutations in tomosyn-2 that increase its
inhibitory activity can create a bottleneck and in the presence of
obesity-induced insulin resistance, tip the balance towards T2D.
However, it is also possible that tomosyn-2 plays an important role
in regulating insulin secretion during daily starve/feed cycles by
preventing inappropriate insulin secretion during fasting.
Tomosyn-2may regulate exocytosis by modulating the formation
of the SNARE complex in tissues other than islets. We observed
significant tomosyn-2 expression in brain, cerebellum, islets, kidney,
liver, and gastrocnemius (Figure 7). Therefore it is possible that
tomosyn-2, like tomosyn-1, may have an important regulatory role
in tissues where regulation of the SNARE complex can be limiting
for an important transport process; e.g. insulin-mediated GLUT4
translocation in adipocytes [35] and transport of LDL-derived
cholesterol from the trans-Golgi network to the endoplasmic
reticulum in hepatocytes [36]. Thus, this tomosyn-2 could be
playing a critical role in regulating vesicle trafficking in other tissues.
In summary, we have identified tomosyn-2 as a gene underlying
a T2D susceptibility QTL on Chr 16. We show that tomosyn-2 is a
negative regulator of insulin secretion. We identified a SNP in
tomosyn-2 that affects the stability of the protein and thus suggest
a molecular mechanism by which allelic variation in this gene
increases diabetes susceptibility. Future studies will focus on the
pathways that link nutrient sensing with the role of tomosyn-2 in
the regulation of insulin secretion.
Materials and Methods
Materials
The enzymatic glucose reagent was purchased from Thermo
Scientific. Insulin in lean mice was measured using a radio-
immunoassy kit from Linco Research (St. Charles, MO). In Lep
ob/ob
mice, insulin was measured with an in-house ELISA using an anti-
insulin antibody from Fitzgerald Industries (Acton, MA). The mouse
anti-myc antibody and Z-Leu-Leu-Leu-al (MG132) were purchased
from Sigma-Aldrich, USA. The mouse secondary antibodies were
purchasefromCellSignalingTechnology(Boston,MA).Glutathione
4B Sepharose beads were purchased from GE Healthcare, USA.
Animals and breeding strategy
The C57BL/6 (B6) and BTBR T
+ tf (BTBR) mice were
intercrossed and were crossed to generate F1 mice. The B6.16
B6
and B6.16
BT mice were created by backcrossing the F1 mice to B6
using microsatellite markers to select for BTBR (or B6 in the case of
B6.16
B6) homozygosity on mouse chromosome 16 in an otherwise
B6 background. The B6.16
BT mice were further backcrossed to B6
with marker assisted selection to create congenic strains. Further
identification of the B6/BTBR genetic boundaries were determined
by SNP sequencing for some of the congenic strains (listed in
Dataset S2. The Lep
ob mutation was introgressed into all strains
using Lep
ob/+ mice as breeders [37]. All mice were maintained at the
Department of Biochemistry, University of Wisconsin-Madison
animal care facility on a 12 h dark-light cycle (6 PM to 6 AM). The
mice were fed Purina Formulab Chow 5008 and water ad libitum.
Figure 9. Effect of proteasomal inhibitor on B6 and BTBR allele
of b-tomosyn-2. A) The mammalian expression plasmid containing
the mock, b-tomosyn-2 (Serine912)-myc or b-tomosyn-2 (Leucine-912)-
myc were transfected in HEK293Tcells. After 16 h incubation in DMEM
supplemental media, cells expressing b-tomosyn-2-myc were treated
with MG132 (100 mM) or DMSO for 6 h. Equal amounts of protein were
subjected to western blot analysis and the level of b-tomosyn-2-myc
protein was determined using anti-myc antibody. The actin was used as
a loading control. B) Shows the quantitation of the signals for three
experiments. Values are means 6 S.E. of N=3. *p#0.05 for the
expression of b-tomosyn-2-myc in the samples treated with MG132 vs.
DMSO.
doi:10.1371/journal.pgen.1002323.g009
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Madison Research Animals Resource Center and the NIH
guidelines for care and use of laboratory animals.
Plasma measurements
For plasma glucose and insulin measurements, blood was taken
from the retro orbital sinus from random fed mice at 8 AM or
from fasting mice at 12 PM (fasted at 8 AM). For both Lep
ob/ob and
lean mice, glucose was measured via glucose oxidase method
(Thermo Scientific). For Lep
ob/ob mice, insulin was measured via
ELISA using a matched rat insulin antibody pair (Fitzgerald
Industries International Inc.). For lean mice, insulin was measured
by Linco Sensitive rat insulin radioimmunoassay.
Islet isolation and insulin secretion assays
Intact pancreatic islets were isolated from mice using a
collagenase digestion procedure [38]. Static insulin secretion
assays were performed on preparations consisting of three islets
incubated with various secretagogues [38]. For perifusion insulin
secretion assays, approximately 100 medium sized islets were
washed three times, placed in a sterile Petri dish, and incubated
overnight in culture media (RPMI 1640, with 11.1mM glucose,
antibiotics and 10% heat inactivated fetal bovine serum). The
following day, 50 islets were washed and transferred in 100 mlo f
Krebs Ringer Buffer (KRB) to the Swinnex filter holder
(Millipore). The islets were sandwiched between two layers of
Bio-Gel P-2 bead (Bio-Rad) solution (200 mg beads/ml in KRB;
bottom layer, 150 ml and top layer, 300 ml). The Swinnex filter
holder was attached in-line with a Minipuls 3 pump (Gilson) and a
FC 204 Fraction Collector (Gilson). Islets were perifused at the
rate of 1ml/min and samples were collected at 30 sec intervals.
Islet insulin content and secretion were determined by ELISA.
Next generation sequencing
Tail DNA was extracted from B6, BTBR, B6.16
BT36–38,
B6.16
BT24–37and B6.16
BT24–38 mice using the QIAGEN Puregene
Core Kit. RNA baits were designed using Agilent eArray and used
for Agilent SureSelect Target Enrichment to capture sequence
from a 35.35 to 38.65 Mb region on mouse chromosome 16.
Target enrichment was followed by DNA amplification and
confirmation of enrichment using SNP sequencing inside and
outside of the target region. DNA was sequenced by Next
Generation Sequencing using an Illumina GA IIx sequencer at the
University of Wisconsin-Madison Biotechnology Center. CLC
Genomics 4.0.3 Software was used to identify SNPs and DIPs
between B6 and BTBR sequence. For some SNPs and DIPs an
additional visual base calling confirmation step was used to test the
accuracy of the software (listed in Dataset S1).
Isolation and quantitation of total RNA
RNA from islets, kidney, and liver was extracted using the
QIAGEN RNeasy Plus Kit. RNA from epididymal fat pads, brain,
cerebellum, and adrenal glands was extracted using QIAGEN
RNeasy Lipid Kit. RNA from heart, soleus, gastrocnemius and
quadriceps was extracted using QIAGEN RNeasy Fibrous Tissue
Kit. Following extraction, RNA was used for cDNA synthesis
(Applied Biosystems). The mRNA abundance was determined by
quantitative PCR using FastStart SYBR Green (Roche) and gene
expression was represented by comparative DCT method.
Plasmids
MMLV-based retroviral vector (RVV, 3051) (gift from Dr. Bill
Sugden,UniversityofWisconsin,Madison)containingaMCS-IRES
GFP was used to generate b-tomosyn-2-RVV construct for
expression studies. The pcDNA3-m-tomosyn-1, pCR-Script-xb, -b,
-m, and s-tomosyn-2 constructs were generously provided by Dr.
Alexander Groffen, Virije Universiteit, Netherlands. We corrected a
mutation (AG) at nucleotide 3245 of the b-Tomosyn-2 cDNA. The
tomosyn-1 or tomosyn-2 cDNA from these vectors were used for
subsequent subcloning. The b-tomosyn-2-RVV construct was
generated by subcloning the b-tomosyn-2 cDNA with 59-BspDI
and 39-NotI overhangs into the compatible 59-BstBI and 39-NotI
ends of the RVV vector. For binding studies, the tomosyn-2-
pcDNA/TO/myc-His was generated by subcloning a PCR-
amplified tomosyn-2 cDNA in to 59-BamHI and 39-XhoI sites of
the pcDNA4/TO/myc-His C vector (Invitrogen). The following
primers that were used to amplify tomosyn-2 cDNA with the
restriction sites for cloning, a partial KOZAK, and a 39-precision
protease cleavage site are: forward (59-TTAAAGGATCCGCCAC-
CATGAAGAAGTTTAATTTCCG) and reverse (59-ATATCTC-
GAGGGGCCCCTGGAACAGAACTTCCAGGAACTGGTAC-
CACTTCTTATCCT). Similar subcloning strategy was used for
generating m-tomosyn-1-pcDNA/TO/myc-His construct. The
primers used are as follows: forward (59-CGAGACCGGATCCGC-
CACCATGAGGAAATTCAACATC) and reverse (59-ATAT-
CTCGAGCCCCTGGAACAGAACTTCCAGGAACTGGTAC-
CACTTCTTATCTTTG) primes. The pGEX-4T1-syntaxin-4
construct encoding soluble GST-syntaxin-4 (1-273) fusion protein
was generated as previously described [39]. The pGEX-2T1-
syntaxinconstruct(1-265) was a generous gift from Dr. Tom Martin,
University of Wisconsin, Madison. All constructs were verified by
sequencing.
Cell culture, transient transfection, and insulin secretion
measurements
The glucose responsive rat b-cell line, INS1 (832/13, a gift from
Dr. Chris Newgard, Duke University) was cultured in RPMI 1640
medium containing 11 mM glucose supplemented with 10% heat
inactivated fetal bovine serum, 2 mM L-glutamine, 1 mM sodium
pyruvate, 10 mM HEPES, 100 Units/ml of antibiotic-antimycot-
ic, and 50 mM b-mercaptoethanol. Approximately 100,000 cells/
well were plated in a 96-well plate. The following day, INS1 (832/
13) cells at 80–90% confluency were transfected with 0.4 mgo f
plasmid DNA using Lipofectamine 2000 (Invitrogen). After 36 h
of incubation, cells were washed once with 200 ml and incubated
for 2 h in 100 ml of modified Krebs-Henseleit Ringer bicarbonate
buffer (KRB: 118.41 mM NaCl, 4.69 mM KCl, 1.18 mM
MgSO4, 1.18 mM KH2PO4, 25 mM NaHCO3, 20 mM HEPES,
2.52 mM CaCl2, pH 7.4, and 0.2% BSA) containing 1.5 mM
glucose. After 2 h, cells were stimulated for 2 h in 100 ml of KRB
buffer containing 7 mM glucose + 3 mM 8-bromo-cAMP. The
incubation buffer was collected to determine the amount of insulin
secreted under varying conditions. The cells were lysed (lysis
buffer: 1 M Tris-HCl, pH 8.0, 1 M NaCl, 0.5 M NaF, 200 mM
Na3VO4, 2% NP-40, and protease inhibitor cocktail tablet
(Roche)) to determine insulin content. The percent fractional
insulin secretion was calculated as the amount of insulin secreted
divided by total insulin content. Insulin was determined using
ELISA.
The human embryonic kidney 293T cells (HEK293T) were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
containing 25 mM glucose were supplemented with 10% fetal
bovine serum, 0.1 mM nonessential amino acid, 6 mM L-
glutamine, 1 mM sodium pyruvate, 100 units/ml of penicillin,
100 units/ml of streptomycin, and 500 mg/ml of geneticin.
HEK293T cells at 70–80% in 100 mm tissue culture dishes were
transfect with plasmid DNA constructs using 40 ml of 1 mg/ml
Positional Cloning of a Type 2 Diabetes QTL
PLoS Genetics | www.plosgenetics.org 9 October 2011 | Volume 7 | Issue 10 | e1002323polyethylenimine. Following day, cells were lysed (lysis buffer:
20 mM Tris-HCl (pH 7.5). 150 mM NaCl, 1 mM Na2EDTA,
1mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM
b-glycerophosphate, 1 mM Na3VO4, 1 mM PMSF, and protease
inhibitor cocktail tablet (Roche)) and total protein lysates were
prepared and the immunoblot was performed as described [40].
For protein stability, 16 h post transfection, cells were treated with
or without 100 mM MG132 for 6 h. After 6 h, cells were lysed and
whole cell lysates were prepared.
Recombinant proteins, in vitro binding assays, and
immunobloting
Recombinant proteins encoding GST or GST-fusion proteins
with the cytoplasmic domain of syntaxin-1A and syntaxin-4 were
expressed in E.Coli strain BL21 (DE3) and were purified using
glutathione-affinity chromatography [41]. The concentration and
the purity of the fusion proteins were assessed by SDS-PAGE
followed by Coomassie-blue staining against BSA standards. The
binding studies were preformed by incubating 10 mg of recombi-
nant proteins with 25 ml of 100% Glutathione-Sepharose 4B beads
(Amersham Biosciences) with 1 mg of HEK293T lysate overex-
pressing tomosyn-1 or isoforms of tomosyn-2 (xb, b, m, and s) in
1% Triton-lysis buffer for 2 h at 4uC. After 2 h, the complexes
were washed three times with Triton lysis buffer and was eluted in
Western loading buffer. The denatured samples were subjected to
10% SDS-PAGE gels followed by transfer to PVDF membrane for
immunoblotting. The immunobloting was performed using a
standard protocol [40].
Statistical analysis
Data was expressed as means 6 standard error of means. The
statistical comparisons were made using Student’s t test at p,0.05.
Supporting Information
Dataset S1 SNPs and DIPs in QTL Region. Single nucleotide
polymorphisms and deletion/insertion polymorphisms (DIPs) in
the 36–38.5 Mb region underlying the chromosome 16 QTL were
determined by Next Generation sequencing. Using the CLC
Genomics 4.0.3 software, for each strain (B6, BTBR, B6.16
BT36–38,
B6.16
BT24–37, and B6.16
BT24–38), an algorithm generated a list of
SNPs/DIPs using published C57BL/6J sequence as the reference.
The algorithm generated a frequency of the SNP/DIP call and only
those above 90% were chosen. From there, we sorted the SNPs/
DIPs for each strain, and only chose those SNPs/DIPs that were
confirmed in at least 3 strains (either one allele for B6 and two for
BTBR or vice versa). They also had to agree with what we already
knew from our marker and SNP typing (see Supplemental File S1).
At that point, to test the validity of the algorithm-generated list, for
those that we call ‘‘confirmed’’ by ‘‘manual base reading’’, we went
back to the 4x10
6 bp sequence that was generated from each strain
and confirmed by looking at the numerous reads at each bp call,
that this was in fact a real SNP/DIP. We were unable to do this for
all SNPs due to time and money constraints, but the accuracy of the
algorithm was very good once we placed the above thresholds on
the data. The three coding SNPs were not de novo discoveries
(although they are not listed in all SNP databases) and were also
confirmed via Sanger sequencing in our strains. We cannot say how
many were de novo discoveries because the SNP data available for
BTBRis verysparseand wehavefounditto be inaccurate.Previous
to embarking on this large-scale sequencing, we used Sanger
sequencing to test over 50 published B6 versus BTBR SNPs from
the JAX database and found that they were not different between
our B6 and BTBR strains; hence the reason for us to do the large-
scalesequencing.TheDIPsthat werediscovered weremostlikelyde
novo discoveries, because we are unaware that such data exists for
DIPs between mouse strains. We did confirm one of these DIPs
(DIP37.7) to further define the boundary of strain B6.16
BTBR37–55.
Included in this file are boundaries of the genes in the region and all
SNPs & DIPsthat satisfied the criteria describedabove.ThoseSNPs
or DIPs that have base calls for each strain in columns F through J
were subject to the above ‘‘manual base reading’’.
(XLS)
Dataset S2 Tomosyn-2 SNPs. Listed are those SNPs/DIPs that
were located upstream and downstream of the tomosyn-2 gene.
We identified 1 non-synonymous coding SNP and 8 intronic SNPs
in tomosyn-2. Three of the intronic SNPs found are not listed in
the MGI database but are listed in UCSC Genome Browser
(rs4173887, rs4173899 and rs46721065). We were unable to
confirm 2 SNPs listed in MGI and UCSC (rs4173886 and
rs4173895). According to published data on the UTR boundaries
for tomosyn-2, there were no SNPs found in either 39 and 59
UTR. In columns G through K are the base calls for the SNPs/
DIPs that were subject to the above ‘‘manual base reading’’.
(XLS)
Dataset S3 SNP map for chromosome 16. Listed are the
microsatellite markers, SNPs and DIPs used to identify the
chromosome 16 B6/BTBR boundaries of our congenic mouse
strains. Only those with a B6 or BT call were tested at each
marker, SNP or DIP. The rest of the region was inferred from
flanking markers.
(XLS)
Dataset S4 Gap data. Within our 36–38.5 Mb region on
chromosome 16 there were 30531 bp of gap sequence (represent-
ing , 1.2% of the region) where there was not sufficient sequence
for both B6 and BTBR. This will be an overestimate of actual
gaps, due to the fact that the sequence from other strains
compared to either B6 or BTBR could still be used to determine
SNPs/DIPs with our criteria. Listed are the bp boundaries of the
missing B6 and BTBR sequence.
(XLS)
Table S1 Strain distribution of S912L SNP. Non-synonymous
coding SNPs identified within Stxbp5l from mouse strains
sequenced at the Sanger Institute. Reference sequence corre-
sponds to C57BL/6NJ. -, indicates no change. Data obtained
from http://www.sanger.ac.uk/cgi-bin/modelorgs/mousegenomes/
snps.pl.
(DOCX)
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